Theradiag SA announced that it has obtained the CE mark for its Cosentyx® monitoring kit (secukinumab), the LISA TRACKER® range’s 12th biotherapy monitoring test, used for treating psoriasis, psoriatic arthritis and ankylosing spondylitis. Cosentyx®/secukinumab is a human monoclonal antibody that blocks the action of IL17A immune system proteins (interleukin). By blocking this substance, it reduces the inflammatory processes liable to have a role in psoriasis, psoriatic arthritis and ankylosing spondylitis.